Background and Objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now …

Background: Predicting disability worsening in multiple sclerosis (MS) remains an important
challenge. Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) seem …

Background In a recent trial, hydroxychloroquine (HCQ) treatment reduced the expected rate
of disability worsening at 18 months in primary progressive multiple sclerosis (PPMS) …

There is debate on the role of glial fibrillary acidic protein (GFAP) as a reliable biomarker in
multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), and its …

Objective There is a lack of sensitive and specific biomarkers for use in progressive multiple
sclerosis (MS). The study aimed to assess the potential of serum neurofilament light chain …

目的探讨脐带血造血干细胞移植(UCBT) 治疗异染性脑白质营养不良(MLD) 的安全性及有效性.
方法回顾性分析2019 年4 月至9 月行非血缘UCBT 治疗的3 例MLD 患儿的临床资料. 结果3 …

Methods For this PhD, an explorative, prospective observational cohort study (the MUST
study) was conducted, from which three studies were included (study I, study II, and study III) …

2 disability biomarker in progressive MS, neurologists would be hard pressed to classify
disability based on serum GFAP measurements, with significant overlap in serum GFAP …

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the
central nervous system that leads to diverse clinical outcomes and disability. It is the most …